Covaxin 77 8% effective against Covid-19: Bharat Bio - The Hindu BusinessLine thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
Bharat Biotech says that the final efficacy analysis of Covaxin shows it to be 77.8 per cent effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission. This paves the way for Covaxin to get World Health Organisation s approval for its inclusion in the Emergency Use List of Covid-19 vaccines. The company added that the analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19. The safety analysis demonstrates that adverse events reported were similar to placebo, with 12 per cent of the subjects experiencing commonly known side effects and less than 0.5 per cent of them feeling serious adverse effects. The efficacy data further demonstrates 63.6 per cent protection against asympt
Covaxin has received emergency use authorizations in 16 countries, Bharat Biotech said.
Highlights
The vaccine offers 65.2 per cent protection against Delta variant
Phase 3 trials were conducted on 130 symptomatic Covid patients
New Delhi:
Bharat Biotech s Covaxin is overall 77.8 per cent effective against Covid, the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed.
The vaccine offers 65.2 per cent protection , it said, against the rapidly emerging Delta variant.
It was also found to be 93.4 per cent effective against severe symptomatic COVID-19, the company said.
Covaxin is a whole virus inactivated vaccine against SARS-CoV2, developed by Bharat Biotech in partnership with ICMR and NIV Pune.
Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid
By IANS |
93 Views
Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid. Image Source: IANS News
New Delhi, July 3 : Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
Bharat Biotech has concluded final analysis for Covaxin efficacy from Phase 3 clinical trials.
Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19. Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects feeling serious adverse events.
Bharat Biotech Concludes Final Analysis for COVAXIN® Efficacy from Phase 3 Clinical Trials indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.